Other equities analysts also recently issued research reports about the stock. Cantor Fitzgerald started coverage on shares of Theravance Biopharma in a research note on Monday, January 28th. They issued a “buy” rating and a $55.00 price objective for the company. Zacks Investment Research downgraded shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a research note on Wednesday, March 13th. Finally, ValuEngine downgraded shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a research note on Tuesday, January 22nd. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $43.40.
Shares of NASDAQ:TBPH opened at $20.62 on Friday. The company has a market capitalization of $1.16 billion, a P/E ratio of -5.17 and a beta of 1.68. Theravance Biopharma has a 52 week low of $20.10 and a 52 week high of $35.48.
In other Theravance Biopharma news, SVP Sharathchandra S. Hegde sold 9,033 shares of Theravance Biopharma stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $24.71, for a total value of $223,205.43. Following the transaction, the senior vice president now directly owns 270,134 shares of the company’s stock, valued at $6,675,011.14. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 6.60% of the stock is currently owned by insiders.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Man Group plc acquired a new stake in shares of Theravance Biopharma during the 3rd quarter worth $292,000. Teachers Advisors LLC lifted its position in shares of Theravance Biopharma by 29.1% during the 3rd quarter. Teachers Advisors LLC now owns 139,815 shares of the biopharmaceutical company’s stock worth $4,568,000 after buying an additional 31,552 shares during the last quarter. TIAA CREF Investment Management LLC lifted its position in shares of Theravance Biopharma by 27.7% during the 3rd quarter. TIAA CREF Investment Management LLC now owns 158,966 shares of the biopharmaceutical company’s stock worth $5,193,000 after buying an additional 34,495 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of Theravance Biopharma by 3.6% during the 3rd quarter. Vanguard Group Inc. now owns 3,672,030 shares of the biopharmaceutical company’s stock worth $119,965,000 after buying an additional 126,135 shares during the last quarter. Finally, FNY Investment Advisers LLC bought a new stake in shares of Theravance Biopharma during the 4th quarter worth $42,000. 85.14% of the stock is currently owned by institutional investors and hedge funds.
About Theravance Biopharma
Theravance Biopharma, Inc, a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines. The company offers VIBATIV, a bactericidal, once-daily injectable antibiotic to treat patients with serious, life-threatening infections due to staphylococcus aureus and other gram-positive bacteria, including methicillin-resistant.
Featured Story: Purposes and Functions of the Federal Reserve
Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.